Skip to main content

Featured

Market Futures Slip as Geopolitical Tensions Weigh on Sentiment

  U.S. stock futures edged lower early Thursday as investors attempted to extend Wednesday’s rebound but remained cautious amid ongoing conflict in the Middle East. Futures tied to the Dow Jones Industrial Average fell about 0.4%, while S&P 500 and Nasdaq 100 futures slipped roughly 0.2% each. The pullback followed a strong regular session in which all three major indexes posted gains, with the Dow snapping a three‑day losing streak.  The overnight weakness reflects persistent market sensitivity to geopolitical developments. Escalating tensions involving the U.S., Israel, and Iran continue to drive volatility across asset classes, with traders closely watching oil prices and inflation implications. Recent sessions have seen markets swing sharply as headlines shift, underscoring the fragile balance between economic fundamentals and geopolitical risk.  Despite the cautious tone, Wednesday’s rally showed that investors are still willing to buy into dips—particularl...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment